Bronchiectasis - Market Insight, Epidemiology And Market Forecast - 2034

Bronchiectasis - Market Insight, Epidemiology And Market Forecast - 2034

Key Highlights

The Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 16,075 million in 2023 and is expected to experience consistent growth during the forecast period (2024–2034). This growth is primarily driven by rising diagnosed prevalent cases and the introduction of emerging therapies.

According to DelveInsight's analysis, it is projected that approximately 41% of the Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented nearly 18.6 million diagnosed prevalent cases of COPD.

In the 7MM, the market primarily comprised of three categories: Monotherapies (including LABA, LAMA, and others), Double Combination Therapies (such as LABA + ICS, LABA + LAMA, and other combinations), and Triple Combination Therapies (such as LABA + LAMA + ICS). Among these, Double Combination Therapies generated the highest market revenue, reaching approximately USD 8,803 million in 2023.

The total market size of the Chronic Obstructive Pulmonary Disease (COPD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Itepekimab (SAR440340/REGN3500), FASENRA (benralizumab), NUCALA (Mepolizumab), and others.

In May 2024, AstraZeneca published the latest research across key respiratory and immune-mediated diseases at ATS 2024, showcasing the strength of its broad pipeline and portfolio, including Benralizumab treatment of patients with COPD

DelveInsight’s “Chronic Obstructive Pulmonary Disease (COPD) – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology and the COPD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM COPD market size from 2020 to 2034. The report also covers current COPD treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Treatment Algorithm

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

The pathogenesis of COPD involves intricate pathological mechanisms, resulting in distinct subgroups with unique characteristics and progression patterns. This diversity contributes to variations in exacerbation frequency, airflow restriction, and impairment of lung function. Difficulties in effectively addressing this diversity pose significant challenges in COPD management.

Chronic Obstructive Pulmonary Disease (COPD) Diagnosis

COPD is often underdiagnosed or misdiagnosed and subsequently undertreated or mistreated. Out of total cases, very few cases are identified. A contributing factor to underdiagnoses is the failure of physicians and patients to recognize the significance of symptoms. Misdiagnosis of COPD is also common, with many patients being labeled as having smoker’s cough, asthma, or a lower respiratory tract infection. The COPD endotypes advocate that some patients exhibit clinical characteristics outside the usual symptom profile. Compared to other diseases whose diagnosis is difficult, COPD diagnosis with spirometry is proven to be effective and objective, non-invasive, sensitive to early change, and reproducible. With the availability of portable instruments, it can be performed almost anywhere and, with the right training, most healthcare practitioners can perform it.

Further details related to diagnosis are provided in the report…

Chronic Obstructive Pulmonary Disease (COPD) Treatment

Medical treatments of COPD include drugs, for example, nicotine replacement therapy, beta-2 agonists and anticholinergic agents (bronchodilators), combined drugs using steroids and long-acting bronchodilators, mucolytic agents, oxygen therapy, and surgical procedures such as bullectomy, lung volume reduction surgery, and lung transplantation.

COPD management faces several challenges, including disease heterogeneity, underdiagnosis, and the need for better tools for diagnosis and assessment. Specific challenges include managing stable and unstable COPD conditions, exacerbations, assessing airflow obstruction severity, risk factors exposure, and comorbidities, as well as symptoms such as breathlessness and exercise intolerance. Pharmacological treatment is often based on the patient's Global Initiative for Obstructive Lung Disease (GOLD) group, with initial therapy tailored to their specific condition.

Further details related to treatment are provided in the report…

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

As the market is derived using the patient-based model, the Chronic Obstructive Pulmonary Disease (COPD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of COPD, Subtype-specific Diagnosed Prevalent Cases of COPD, Gender-specific Diagnosed Prevalent Cases of COPD, Age-specific Diagnosed Prevalent Cases of COPD, Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that approximately 44.2 million Diagnosed Prevalent Cases of COPD were found in 2023 in the 7MM.

The United States exhibited the highest diagnosed prevalent population of COPD, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Diagnosed Prevalent Cases of COPD in the US was around 18.3 million in 2023 and is projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis and increasing awareness among the patient population.

According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of COPD in EU4 and the UK were found to be ~18.6 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of COPD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.

The estimates show the Total Diagnosed Prevalent Cases of COPD in Japan was found to be around 7.2 million in 2023, which is estimated to increase by 2034 at a significant CAGR.

The Gender-specific Cases of COPD in the UK were ~1.7 million for females and ~2 million for males in 2023 and are expected to increase within the forecast period (2024–2034). The increased prevalence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.

According to the analysis performed by DelveInsight's experts, the Age-specific Cases of COPD were categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years. The higher number of cases (~4.8 million) was accounted for by the 55-64 year age group in 2023 in the US.

The Diagnosed Prevalence of COPD Based on Severity of Airflow Limitation was categorized into GOLD (Global Initiative for Chronic Obstructive Lung Disease) 1–4. According to DelveInsight estimates, a higher number of patients were estimated in the GOLD 2 category, with approximately 1.9 million cases in 2023 in Germany.

The GOLD guidelines combine FEV1 reduction, dyspnea, and exacerbation history to classify patients with COPD into Groups A–D. According to estimations by DelveInsight’s analysts, the Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History were higher in the GOLD A category in the US with nearly 9.8 million cases in 2023.

Chronic Obstructive Pulmonary Disease (COPD) Drug Chapters

The drug chapter segment of the COPD report encloses a detailed analysis of COPD marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands COPD clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca

Approved in April 2019, Duaklir (aclidinium bromide/formoterol fumarate 400 µg/12 µg twice-daily) is a fixed-dose LAMA/LABA combination of two long-acting bronchodilators – aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). Duaklir Pressair contains two bronchodilators: aclidinium, a long-acting muscarinic antagonist (also known as an anticholinergic), and formoterol, a long-acting beta-2-adrenergic agonist.

DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting the alpha chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged =12 with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. The drug is currently in Phase III of clinical development for COPD.

In September 2024, the US FDA approved DUPIXENT (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype.

Note: Detailed marketed therapies assessment will be provided in the final report of Chronic Obstructive Pulmonary Disease (COPD).

Emerging Drugs

Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for COPD.

In January 2023, itepekimab received FTD from the US FDA for the treatment of COPD.

FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab), currently in Phase III, is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. Besides, it is an afucosylated IgG which gives it a high affinity for the Fc?RIIIa receptor in natural killer cells, macrophages, and neutrophils.

Note: Detailed emerging therapies assessment will be provided in the final report of Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

COPD is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. Abnormalities in the lungs’ small airways lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be the destruction of parts of the lung, mucus blocking the airways, inflammation, and swelling of the airway lining. COPD and asthma share common symptoms (coughing, wheezing, and difficulty breathing), and people may have both conditions.

Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal of treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. COPD treatment focuses on relieving symptoms, such as coughing and breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD.

There are specific lifestyle changes required to prevent COPD. Quitting smoking is an essential step in any treatment plan for COPD. Stopping smoking can keep COPD from getting worse and reducing the ability to breathe. In addition to this, physical activity can strengthen the muscles that help breathe and improve overall wellness.

Pharmacotherapy for COPD consists of maintenance and reliever medications. Maintenance medications included inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), fixed-dose combination ICS + LABA, tiotropium, and inhaled ipratropium or fixed-dose combination ipratropium + albuterol (collectively referred to as ipratropium [IPR]). Reliever medications included short-acting beta-agonist (SABA), oral corticosteroid, nebulized ipratropium or combination ipratropium–albuterol (collectively referred to as nebulized ipratropium [nebIPR]), and antibiotics.

Several kinds of medications are used to treat COPD symptoms and complications, including bronchodilators, which relax the muscles around the airways. This helps open the airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler can also contain steroids to reduce inflammation. Some of the short-acting and long-acting bronchodilators that are used in management include Albuterol (ProAir HFA, Ventolin HFA, and others), Ipratropium (ATROVENT HFA), Levalbuterol (XOPENEX), Aclidinium (TUDORZA PRESSAIR), Arformoterol (BROVANA), Formoterol (PERFOROMIST), etc.

The market for COPD is expected to experience positive growth with the approval of potential drugs like Itepekimab (SAR440340/REGN3500), FASENRA (benralizumab), NUCALA (Mepolizumab), and others.

The total market size of COPD in the 7MM reached approximately USD 16,075 million in 2023. Projections indicate a substantial growth during the forecast period.

Out of the 7MM, the United States dominated the market in 2023, representing the largest share at nearly 62%.

In 2023, EU4 and the UK captured an estimated USD 3,361 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2023, followed by Italy, France, and Spain. The UK accounted for the least market in the same year.

Japan alone represented approximately 17% of the total COPD market in 2023, projected to increase at a substantial CAGR during the study period.

The total market size of the COPD treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020–2034. For example, Itepekimab in the US is expected to be launched by 2025 with a peak shared of 2%.

Further detailed analysis of emerging therapies drug uptake in the report…

Chronic Obstructive Pulmonary Disease (COPD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for COPD emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on COPD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Holy Cross Hospital, USA, Hospital Universitario de Guadalajara, Spain, Instituto de Investigación Sanitaria Gregorio Marañón, Spain, Tokyo Women's Medical University, Japan, The University of Sheffield, UK, University of Rome, Italy, and others.

Delveinsight’s analysts connected with 40+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or COPD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Chronic Obstructive Pulmonary Disease (COPD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.

Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.

A detailed review of the Chronic Obstructive Pulmonary Disease (COPD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Chronic Obstructive Pulmonary Disease (COPD) market.

Chronic Obstructive Pulmonary Disease (COPD) Report Insights

Patient Population

Therapeutic Approaches

Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis

Chronic Obstructive Pulmonary Disease (COPD) Market Size and Trends

Existing and Future Market Opportunity

Chronic Obstructive Pulmonary Disease (COPD) Report Key Strengths

11 years Forecast

The 7MM Coverage

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Segmentation

Key Cross Competition

Conjoint Analysis

Drugs Uptake and Key Market Forecast Assumptions

Chronic Obstructive Pulmonary Disease (COPD) Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions

Market Insights

What was the Chronic Obstructive Pulmonary Disease (COPD) total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?

What unmet needs are associated with the current treatment market of Chronic Obstructive Pulmonary Disease (COPD)?

What are the patents of emerging therapies for Chronic Obstructive Pulmonary Disease (COPD)?

Which drug is going to be the largest contributor by 2034?

What are the pricing variations among different geographies for approved and off-label therapies?

How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Chronic Obstructive Pulmonary Disease (COPD)? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Obstructive Pulmonary Disease (COPD)?

What is the historical and forecasted Chronic Obstructive Pulmonary Disease (COPD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for Chronic Obstructive Pulmonary Disease (COPD) and why?

What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current options for treating Chronic Obstructive Pulmonary Disease (COPD)? What are the current guidelines for treating Chronic Obstructive Pulmonary Disease (COPD) in the US and Europe?

How many companies are developing therapies for treating Chronic Obstructive Pulmonary Disease (COPD)?

How many emerging therapies are in the mid-stage and late stage of development for treating Chronic Obstructive Pulmonary Disease (COPD)?

What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?

What are the key designations that have been granted for the emerging therapies for Chronic Obstructive Pulmonary Disease (COPD)?

Patient acceptability in terms of preferred treatment options as per real-world scenarios?

What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

What are the 7MM historical and forecasted markets of Chronic Obstructive Pulmonary Disease (COPD)?

Reasons to Buy

The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Obstructive Pulmonary Disease (COPD) Market.

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the existing market opportunity in varying geographies and the growth potential over the coming years.

Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.

Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.

Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.

To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Chronic Obstructive Pulmonary Disease (COPD) market?

The Chronic Obstructive Pulmonary Disease (COPD) market is quite robust. The major layers are Verona Pharma, AstraZeneca, Covis, Viatris Inc., GlaxoSmithKline, Novartis, Boehringer Ingelheim, and others which are currently developing drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Chronic Obstructive Pulmonary Disease (COPD) market?

The increase in diagnosed prevalent cases of Chronic Obstructive Pulmonary Disease (COPD) and the launch of emerging therapies are attributed to be the key drivers for increasing Chronic Obstructive Pulmonary Disease (COPD) market.

5. What is the expected impact of emerging therapies or advancements in Chronic Obstructive Pulmonary Disease (COPD) treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Chronic Obstructive Pulmonary Disease (COPD) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Chronic Obstructive Pulmonary Disease (COPD) market.